MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
Log in

NASDAQ:OPKOpko Health Stock Price, Forecast & News

$4.09
+0.07 (+1.74 %)
(As of 07/10/2020 09:48 AM ET)
Add
Compare
Today's Range
$3.95
Now: $4.09
$4.14
50-Day Range
$2.15
MA: $2.71
$4.08
52-Week Range
$1.12
Now: $4.09
$4.27
Volume763,114 shs
Average Volume13.71 million shs
Market Capitalization$2.74 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.29
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Read More
Opko Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$901.90 million
Book Value$2.43 per share

Profitability

Net Income$-314,920,000.00

Miscellaneous

Employees6,096
Market Cap$2.74 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

Opko Health (NASDAQ:OPK) Frequently Asked Questions

How has Opko Health's stock been impacted by COVID-19 (Coronavirus)?

Opko Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPK shares have increased by 142.0% and is now trading at $4.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Opko Health?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opko Health.

When is Opko Health's next earnings date?

Opko Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Opko Health.

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.09). The biotechnology company earned $211.50 million during the quarter, compared to analyst estimates of $215.93 million. Opko Health had a negative net margin of 32.92% and a negative return on equity of 13.56%. View Opko Health's earnings history.

What price target have analysts set for OPK?

3 brokers have issued 12-month target prices for Opko Health's shares. Their forecasts range from $2.50 to $6.00. On average, they expect Opko Health's share price to reach $4.17 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price. View analysts' price targets for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

Media stories about OPK stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Opko Health earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Opko Health.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 117,000,000 shares, an increase of 6.8% from the June 15th total of 109,540,000 shares. Based on an average daily volume of 13,220,000 shares, the short-interest ratio is presently 8.9 days. Currently, 29.0% of the company's stock are short sold. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), bluebird bio (BLUE), Gray Television (GTN), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Allergan (AGN), AT&T (T) and Alibaba Group (BABA).

Who are Opko Health's key executives?

Opko Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Who are Opko Health's major shareholders?

Opko Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.01%). Company insiders that own Opko Health stock include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View institutional ownership trends for Opko Health.

Which institutional investors are buying Opko Health stock?

OPK stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel, and Steven D Rubin. View insider buying and selling activity for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $4.09.

How big of a company is Opko Health?

Opko Health has a market capitalization of $2.74 billion and generates $901.90 million in revenue each year. The biotechnology company earns $-314,920,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Opko Health employs 6,096 workers across the globe.

What is Opko Health's official website?

The official website for Opko Health is www.opko.com.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.